✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Darinaparsin is an investigational drug.
There have been 12 clinical trials for Darinaparsin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2007.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, Peripheral, and Lymphoma, T-Cell. The leading clinical trial sponsors are Ziopharm, Solasia Pharma K.K., and Synex Consulting Korea Ltd.
Recent Clinical Trials for Darinaparsin
|A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)||Solasia Pharma K.K.||Phase 2|
|A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea||Synex Consulting Korea Ltd.||Phase 1|
|A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea||Solasia Pharma K.K.||Phase 1|